

**STI PHARMACEUTICALS LIMITED  
FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2023**

Hill Wooldridge Accountants Ltd  
Chartered Certified Accountants  
55 Crown Street  
Brentwood  
Essex  
CM14 4BD

**STI Pharmaceuticals Limited**  
**Financial Statements**  
**For The Year Ended 31 March 2023**

---

**Contents**

	<b>Page</b>
Balance Sheet	1—2
Notes to the Financial Statements	3—5

**STI Pharmaceuticals Limited**  
**Balance Sheet**  
**As At 31 March 2023**

Registered number: 05003757

		<b>2023</b>		<b>2022</b>	
	<b>Notes</b>	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>
<b>FIXED ASSETS</b>					
Intangible Assets	<b>4</b>		6,311		4,843
Tangible Assets	<b>5</b>		2,770		4,244
			9,081		9,087
<b>CURRENT ASSETS</b>					
Stocks	<b>6</b>	10,000		25,000	
Debtors	<b>7</b>	976		16,820	
Cash at bank and in hand		7,731		9,843	
		18,707		51,663	
<b>Creditors: Amounts Falling Due Within One Year</b>	<b>8</b>	(21,489 )		(35,425 )	
<b>NET CURRENT ASSETS (LIABILITIES)</b>			(2,782 )		16,238
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>					
			6,299		25,325
<b>NET ASSETS</b>					
			6,299		25,325
<b>CAPITAL AND RESERVES</b>					
Called up share capital	<b>9</b>		51		51
Capital redemption reserve			49		49
Profit and Loss Account			6,199		25,225
<b>SHAREHOLDERS' FUNDS</b>			6,299		25,325

**STI Pharmaceuticals Limited**  
**Balance Sheet (continued)**  
**As At 31 March 2023**

---

For the year ending 31 March 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime.

The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.

On behalf of the board

-----

Mr Andrew Davies

Director

16th June 2023

The notes on pages 3 to 5 form part of these financial statements.

**STI Pharmaceuticals Limited**  
**Notes to the Financial Statements**  
**For The Year Ended 31 March 2023**

---

**1. General Information**

STI Pharmaceuticals Limited is a private company, limited by shares, incorporated in England & Wales, registered number 05003757. The registered office is 55 Crown Street, Brentwood, Essex, CM14 4BD.

**2. Accounting Policies**

**2.1. Basis of Preparation of Financial Statements**

The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

**2.2. Turnover**

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover is reduced for estimated customer returns, rebates and other similar allowances.

**Sale of goods**

Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods has transferred to the buyer. This is usually at the point that the customer has signed for the delivery of the goods.

**Rendering of services**

Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.

**2.3. Intangible Fixed Assets and Amortisation - Intellectual Property**

Intellectual property assets are patents and development costs. They are amortised to the profit and loss account over their estimated economic life of 10 years.

**2.4. Tangible Fixed Assets and Depreciation**

Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Plant & Machinery	Dep'n at 25% of cost per year
Fixtures & Fittings	Dep'n at 10% of cost per year

**2.5. Stocks and Work in Progress**

Stocks and work in progress are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads. Work-in-progress is reflected in the accounts on a contract by contract basis by recording turnover and related costs as contract activity progresses.

**2.6. Foreign Currencies**

Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.

**STI Pharmaceuticals Limited**  
**Notes to the Financial Statements (continued)**  
**For The Year Ended 31 March 2023**

**2.7. Taxation**

Income tax expense represents the sum of the tax currently payable.

The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other year and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

**3. Average Number of Employees**

Average number of employees, including directors, during the year was: 1 (2022: 2)

**4. Intangible Assets**

	<b>Intellectual Property £</b>
<b>Cost</b>	
As at 1 April 2022	29,814
Additions	2,940
As at 31 March 2023	<u>32,754</u>
<b>Amortisation</b>	
As at 1 April 2022	24,971
Provided during the period	1,472
As at 31 March 2023	<u>26,443</u>
<b>Net Book Value</b>	
As at 31 March 2023	<u>6,311</u>
As at 1 April 2022	<u>4,843</u>

**5. Tangible Assets**

	<b>Plant &amp; Machinery £</b>	<b>Fixtures &amp; Fittings £</b>	<b>Total £</b>
<b>Cost</b>			
As at 1 April 2022	15,473	6,918	22,391
As at 31 March 2023	<u>15,473</u>	<u>6,918</u>	<u>22,391</u>
<b>Depreciation</b>			
As at 1 April 2022	14,687	3,460	18,147
Provided during the period	782	692	1,474
As at 31 March 2023	<u>15,469</u>	<u>4,152</u>	<u>19,621</u>

...CONTINUED

**STI Pharmaceuticals Limited**  
**Notes to the Financial Statements (continued)**  
**For The Year Ended 31 March 2023**

**Net Book Value**

As at 31 March 2023	4	2,766	2,770
As at 1 April 2022	786	3,458	4,244

**6. Stocks**

	<b>2023</b>	<b>2022</b>
	<b>£</b>	<b>£</b>
Stock	10,000	25,000
	<u>10,000</u>	<u>25,000</u>

**7. Debtors**

	<b>2023</b>	<b>2022</b>
	<b>£</b>	<b>£</b>
<b>Due within one year</b>		
Trade debtors	-	14,184
VAT	976	1,057
Other taxes and social security	-	1,579
	<u>976</u>	<u>16,820</u>

**8. Creditors: Amounts Falling Due Within One Year**

	<b>2023</b>	<b>2022</b>
	<b>£</b>	<b>£</b>
Accruals and deferred income	673	5,334
Directors' loan accounts	20,816	30,091
	<u>21,489</u>	<u>35,425</u>

**9. Share Capital**

	<b>2023</b>	<b>2022</b>
	<b>£</b>	<b>£</b>
Allotted, Called up and fully paid	<u>51</u>	<u>51</u>

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.